Welcome to our dedicated page for YD Bio SEC filings (Ticker: YDES), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
YD Bio Limited (NASDAQ: YDES) files reports with the U.S. Securities and Exchange Commission as a foreign private issuer, providing investors with detailed information on its biotechnology operations, governance, and capital markets activities. On this page, you can review YD Bio’s SEC filings, including Form 6‑K current reports that describe significant corporate events and financial disclosures related to its DNA methylation‑based cancer detection technology, ophthalmologic innovations, and clinical‑trial supply business.
Recent Form 6‑K filings referenced by the company include unaudited interim financial statements and management’s discussion and analysis for YD Bio and its subsidiary YD Biopharma, pro forma financial information following its business combination with Breeze Holdings Acquisition Corp., and press releases furnished as exhibits. Other 6‑K reports detail changes in the company’s independent registered public accounting firm, including the termination of CBIZ CPAs P.C. and the engagement of ARK Pro CPA & Co, as well as the resignation and appointment of audit committee leadership and notices related to Nasdaq director independence requirements.
Investors can also use YD Bio’s filings to track matters such as registration statements affecting the exercisability of publicly traded warrants (YDESW), disclosures about going‑concern explanatory paragraphs in prior audit reports, and information on how the company structures its reporting as a foreign private issuer under Form 20‑F. These documents help explain how YD Bio manages financial reporting, auditor relationships, and board composition while it advances programs in oncology diagnostics and limbal stem cell and exosome therapies.
Stock Titan’s SEC filings page for YDES is designed to surface these regulatory documents quickly, alongside AI‑powered summaries that highlight key points such as changes in auditors, governance updates, and links between financial disclosures and the company’s stated strategy. Users can review Form 6‑K exhibits, interim financials, and other submitted materials to better understand YD Bio’s risk factors, capital structure, and operational priorities.
YD Bio Limited reports that Chief Operating Officer Ms. May Tsai resigned on September 24, 2025 for personal health reasons. The company states her departure was not due to any disagreement over operations, policies, or practices and has begun searching for a new COO.
Following her resignation, YD Bio engaged Ms. Nina Wu as a strategic consultant to support investor communications and manage interactions with capital markets, drawing on her prior roles in real estate and investment promotion in Taiwan.
YD Bio also highlights a Form F-1 registration statement filed on September 23, 2025 to register ordinary shares held by certain shareholders and shares issuable upon exercise of private placement warrants, and plans to amend it to register ordinary shares underlying its publicly traded warrants listed as YDESW. The public warrants will only become exercisable once the amended registration statement is declared effective, while during any period when the registration covering the underlying ordinary shares is not effective, including after the 60th business day following the business combination closing, holders may exercise on a cashless basis.
YD Bio Limited reports a change in its independent auditor. On September 16, 2025, the company ended its engagement with CBIZ CPAs P.C. as its independent registered public accounting firm, with the decision approved by both the audit committee and the board of directors.
CBIZ CPAs’ reports on YD Bio’s consolidated financial statements since inception on February 6, 2024 contained no adverse or disclaimed opinions and were not qualified, although they included an explanatory paragraph raising substantial doubt about the company’s ability to continue as a going concern. The company states there were no disagreements with CBIZ CPAs on accounting, disclosure, or audit matters, and none of the specified reportable events under Item 16F of Form 20-F occurred.
Effective September 17, 2025, YD Bio engaged ARK Pro CPA & Co as its new independent registered public accounting firm for the fiscal year ending December 31, 2025, with no prior consultations on accounting or audit opinions reported.